{"protocolSection": {"identificationModule": {"nctId": "NCT00697697", "orgStudyIdInfo": {"id": "MAP0010-CL-P301X"}, "organization": {"fullName": "Allergan", "class": "INDUSTRY"}, "briefTitle": "A Study of 2 Doses of MAP0010 in Asthmatic Children", "officialTitle": "A Randomized, Double-blind, Active-controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study)"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "TERMINATED", "whyStopped": "Corporate decision", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-12", "studyFirstSubmitQcDate": "2008-06-12", "studyFirstPostDateStruct": {"date": "2008-06-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-08-19", "resultsFirstSubmitQcDate": "2013-08-19", "resultsFirstPostDateStruct": {"date": "2013-10-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-09", "lastUpdatePostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Allergan", "class": "INDUSTRY"}, "collaborators": [{"name": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthmatic children"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 192, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "0.135mg MAP0010", "type": "EXPERIMENTAL", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks", "interventionNames": ["Drug: 0.135mg MAP0010"]}, {"label": "0.25mg MAP0010", "type": "EXPERIMENTAL", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks", "interventionNames": ["Drug: 0.25mg MAP0010"]}], "interventions": [{"type": "DRUG", "name": "0.135mg MAP0010", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks", "armGroupLabels": ["0.135mg MAP0010"]}, {"type": "DRUG", "name": "0.25mg MAP0010", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks", "armGroupLabels": ["0.25mg MAP0010"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients With Treatment Emergent Adverse Events Related to Study Drug", "description": "A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.", "timeFrame": "40 weeks"}, {"measure": "Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination", "description": "A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.", "timeFrame": "40 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Completed 12 weeks of treatment in the MAP0010-CL-P301 study.\n* Patient, parent, and guardian (as appropriate) are willing for child to undergo all study procedures and willing to sign the informed consent and assent, as appropriate.\n\nExclusion Criteria:\n\n* Less than 80% compliance with either study treatment and/or other study procedures (e.g., completion of symptom e-diary) in the MAP0010-CL-P301 Study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Months", "maximumAge": "8 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "MAP Pharmaceuticals", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "0.135mg MAP0010", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}, {"id": "FG001", "title": "0.25mg MAP0010", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "94"}, {"groupId": "FG001", "numSubjects": "98"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "54"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Subjects were randomly assigned to treatment.", "groups": [{"id": "BG000", "title": "0.135mg MAP0010", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}, {"id": "BG001", "title": "0.25mg MAP0010", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "192"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.6", "spread": "2.50"}, {"groupId": "BG001", "value": "4.9", "spread": "2.03"}, {"groupId": "BG002", "value": "4.8", "spread": "2.27"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.0", "lowerLimit": "1", "upperLimit": "9"}, {"groupId": "BG001", "value": "5.0", "lowerLimit": "1", "upperLimit": "8"}, {"groupId": "BG002", "value": "5.0", "lowerLimit": "1", "upperLimit": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "83"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "109"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients With Treatment Emergent Adverse Events Related to Study Drug", "description": "A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.", "populationDescription": "All patients who received any study drug and who had at least one post safety evaluation were included in the adverse event analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "40 weeks", "groups": [{"id": "OG000", "title": "0.135mg MAP0010", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}, {"id": "OG001", "title": "0.25mg MAP0010", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "PRIMARY", "title": "Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination", "description": "A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.", "populationDescription": "All patients who received any study drug and who had at least one post safety evaluation were included in the adverse event analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "40 weeks", "groups": [{"id": "OG000", "title": "0.135mg MAP0010", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}, {"id": "OG001", "title": "0.25mg MAP0010", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All patients who received any study drug and who had at least one post safety evaluation were included in the adverse event analysis.", "eventGroups": [{"id": "EG000", "title": "0.135mg MAP0010", "description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 94, "otherNumAffected": 71, "otherNumAtRisk": 94}, {"id": "EG001", "title": "0.25mg MAP0010", "description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 98, "otherNumAffected": 85, "otherNumAtRisk": 98}], "seriousEvents": [{"term": "Acquired hydrocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}], "otherEvents": [{"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 98}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 98}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 98}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 98}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 98}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 98}]}, {"term": "Viral Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 98}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 98}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 98}]}, {"term": "Rhinitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 98}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 98}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 98}]}, {"term": "Otitis Media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 98}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was terminated due to a corporate decision before all subjects had completed the study."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "VP, Scientific Affairs", "organization": "MAP Pharmaceuticals, Inc. a wholly owned subsidiary of Allergan", "email": "dkellerman@mappharma.com", "phone": "650-386-3100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21711", "name": "Budesonide", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}